A Phase 2 interventional study of Rosuvastatin and Atorvastatin in Hyperlipidemia, sponsored by AstraZeneca. Completed at 107 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-16.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing rosuvastatin in Hyperlipidemias — 1 open to participants now, 1 under way, none of them phase 3. rosuvastatin · Hyperlipidemias.
Among the 30 studies testing rosuvastatin in Hyperlipidemias, this one is the 10th largest by enrollment, is one of 2 that started in 2006, is one of 4 in phase 2, and was the 3rd registered.
862 studies on the registry are indexed under Hyperlipidemias; 108 are open to participants now.
Browse Hyperlipidemias studies →1 of the 30 studies testing rosuvastatin in Hyperlipidemias is open now, in 1 country. Recruiting first, the newest first:
Prof. Maurovich-Horvat Pál · Sites in Hungary
Ages 45–75
By country, each count listing its studies:
rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →
Of the 66 Hyperlipidemias studies recruiting now, 26 (39%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 5 · Phase 3 8 · Phase 4 10
First in 2004; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 237 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 114 across the 30 interventional studies. Of the 22 that completed or were terminated, 8 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 30 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
20 studies in Hyperlipidemias by AstraZeneca: none open now, none under way, none of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 20 studies in Hyperlipidemias by AstraZeneca, this one is the 7th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2006, is one of 3 in phase 2, and was the 1st registered.
AstraZeneca’s Hyperlipidemias studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 30 studies testing rosuvastatin in Hyperlipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 20 in Hyperlipidemias:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in non-diabetes with moderate proteinuria and hypercholesterolaemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Also known as: Crestor
Urinary Protein/Creatinine Ratio at Week 52 [LOCF]
Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine protein/creatinine ratio over baseline urine protein/creatinine ratio.
Time frame: Assessed at baseline and Week 52 (LOCF)
Urinary Protein/Creatinine Ratio at Week 26.
Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine protein/creatinine ratio over baseline urine protein/creatinine ratio.
Time frame: Assessed at baseline and Week 26
Urinary Albumin/Creatinine Ratio at Week 26
Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.
Time frame: Assessed at baseline and Week 26
Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]
Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.
Time frame: Assessed at baseline and Week 52 [LOCF]
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26
The change from baseline in eGFR at Week 26 is the Week 26 value minus baseline value.
Time frame: Assessed at baseline and Week 26
Change From Baseline in eGFR at Week 52 [LOCF]
The change from baseline in eGFR at Week 52 \[LOCF\] is the Week 52 value or last observation carried forward minus baseline value.
Time frame: Assessed at baseline and Week 52 [LOCF]
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 26.
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: baseline and 26 weeks
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 52.
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: 52 weeks
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 26
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline inUrinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: 52 weeks
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in High Density Lipoprotein Cholesterol [HDL-C] at Week 26
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: 26 weeks
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol [nonHDL-C] at Week 26
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship. )
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Triglyceride [TG] at Week 26
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TG at Week 52
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein A-1 [ApoA-1] at Week 26
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein B [ApoB] at Week 26
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 26
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 52
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 26
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 52
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 26
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 26
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 26
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 52
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 26
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 26
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: 52 weeks
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 26
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 52
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 26
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 52
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 26
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 52
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 26
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 52
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG at Week 26
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 26
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 52
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 26
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 52
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 26
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 52
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 26 weeks
Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Time frame: Baseline and 52 weeks
797 patients entered the study with moderate proteinuria and hypercholesterolemia and were receiving stable treatment with angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs) for 3 or more months prior to Visit 1. The study was conducted at 114 participating centers in 11 countries.
| Milestone | Rosuvastatin 10 mg | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|---|
| Started | 70 | 87 | 80 |
| Completed | 53 | 69 | 67 |
| Not completed | 17 | 18 | 13 |
| Withdrew: Adverse event | 7 | 7 | 7 |
| Withdrew: Withdrawal by subject | 5 | 6 | 2 |
| Withdrew: Incorrect enrollment | 2 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 2 |
| Withdrew: Study specific discontinuation criteria | 0 | 0 | 1 |
| Withdrew: Visit 10 was performed earlier | 0 | 1 | 0 |
| Withdrew: Pregnancy | 1 | 2 | 0 |
Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine protein/creatinine ratio over baseline urine protein/creatinine ratio.
| ratio | Rosuvastatin 10 mg | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|---|
| Urinary Protein/Creatinine Ratio at Week 52 [LOCF] | 0.938 (0.725 to 1.212) | 1.082 (0.927 to 1.262) | 0.759 (0.636 to 0.905) |
Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine protein/creatinine ratio over baseline urine protein/creatinine ratio.
| ratio | Rosuvastatin 10 mg | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|---|
| Urinary Protein/Creatinine Ratio at Week 26. | 0.932 (0.721 to 1.203) | 1.057 (0.898 to 1.244) | 0.762 (0.631 to 0.921) |
Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.
| ratio | Rosuvastatin 10 mg | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|---|
| Urinary Albumin/Creatinine Ratio at Week 26 | 0.850 (0.631 to 1.143) | 0.946 (0.789 to 1.135) | 0.731 (0.601 to 0.889) |
Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.
| ratio | Rosuvastatin 10 mg | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|---|
| Urinary Albumin/Creatinine Ratio at Week 52 [LOCF] | 0.879 (0.652 to 1.185) | 0.967 (0.814 to 1.148) | 0.719 (0.587 to 0.882) |
The change from baseline in eGFR at Week 26 is the Week 26 value minus baseline value.
| mL/min | Rosuvastatin 10 mg | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|---|
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26 | 1.39 ± 15.431 | -3.41 ± 13.228 | -1.61 ± 9.494 |
The change from baseline in eGFR at Week 52 \[LOCF\] is the Week 52 value or last observation carried forward minus baseline value.
| mL/min | Rosuvastatin 10 mg | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|---|
| Change From Baseline in eGFR at Week 52 [LOCF] | -2.71 ± 13.083 | -3.30 ± 12.325 | -1.74 ± 13.964 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 26. | 0.17601 | 0.21701 | 0.19643 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 52. | 0.20462 | 0.03480 | 0.16077 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 26 | 0.14302 | 0.24393 | 0.17632 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline inUrinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C | 0.16868 | -0.09428 | 0.10679 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in High Density Lipoprotein Cholesterol [HDL-C] at Week 26 | 0.18055 | 0.24987 | 0.22094 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52 | 0.20346 | 0.18041 | 0.20818 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship. )
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Non-high Density Lipoprotein Cholesterol [nonHDL-C] at Week 26 | 0.16206 | 0.20032 | 0.17628 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52 | 0.20386 | -0.04698 | 0.14495 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Triglyceride [TG] at Week 26 | 0.15348 | -0.06049 | 0.10089 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TG at Week 52 | 0.20659 | 0.23989 | 0.21728 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26 | 0.04652 | 0.06344 | 0.04149 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52 | 0.03957 | -0.17644 | -0.01549 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26 | 0.06383 | 0.12687 | 0.07462 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52 | 0.05881 | -0.20262 | -0.01340 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26 | 0.06794 | 0.05410 | 0.05465 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52 | 0.07188 | -0.16669 | 0.00955 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein A-1 [ApoA-1] at Week 26 | 0.12595 | 0.05628 | 0.13754 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52 | 0.19626 | 0.09835 | 0.18349 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Apolipoprotein B [ApoB] at Week 26 | 0.18504 | 0.17259 | 0.19146 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52 | 0.18473 | -0.02690 | 0.12496 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26 | 0.10698 | 0.13814 | 0.11414 |
Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52 | 0.05859 | -0.12938 | -0.00540 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 26 | 0.18188 | 0.17503 | 0.18566 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC at Week 52 | 0.23734 | 0.01311 | 0.17958 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 26 | 0.14783 | 0.21561 | 0.16899 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C at Week 52 | 0.20285 | -0.13565 | 0.12568 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 26 | 0.23547 | 0.25043 | 0.25208 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in HDL-C at Week 52 | 0.17479 | 0.18677 | 0.18203 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 26 | 0.16080 | 0.17150 | 0.16578 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C at Week 52 | 0.24107 | -0.08640 | 0.16525 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 26 | 0.11526 | -0.06890 | 0.07248 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TG at Week 52 | 0.21730 | 0.21151 | 0.21477 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 26 | 0.02506 | 0.02201 | 0.01860 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in TC/HDL-C Ratio at Week 52 | 0.08954 | -0.20870 | 0.01926 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26 | 0.05037 | 0.09779 | 0.05936 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52 | 0.10365 | -0.24717 | 0.01386 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26 | 0.04955 | 0.02740 | 0.03798 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52 | 0.11997 | -0.21073 | 0.03955 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 26 | 0.16499 | 0.02609 | 0.15049 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoA-1 at Week 52 | 0.20021 | 0.12953 | 0.18870 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 26 | 0.18720 | 0.16167 | 0.18717 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB at Week 52 | 0.21082 | -0.04379 | 0.14085 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26 | 0.10258 | 0.13505 | 0.11103 |
Correlation of changes from baseline in urinary albumin/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in Urinary Albumin/Creatinine Ratio With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52 | 0.08108 | -0.16753 | 0.00479 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 26 | 0.06641 | -0.07964 | 0.02900 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in TC at Week 52 | -0.15721 | 0.16110 | -0.05794 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 26 | 0.02679 | -0.07603 | -0.00171 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in LDL-C at Week 52 | -0.15731 | 0.15368 | -0.06310 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 26 | 0.01684 | 0.01755 | 0.01758 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Changes From Baseline in eGFR With Percent Change From Baseline in HDL-C at Week 52 | 0.14080 | 0.02750 | 0.09472 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 26 | 0.06029 | -0.08151 | 0.02283 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C at Week 52 | -0.19532 | 0.14967 | -0.09001 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG at Week 26 | 0.04160 | 0.00531 | 0.03430 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TG | -0.12643 | 0.00486 | -0.08301 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 26 | 0.08194 | -0.06576 | 0.04477 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in TC/HDL-C Ratio at Week 52 | -0.23597 | 0.19933 | -0.10205 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 26 | 0.04858 | -0.05535 | 0.02023 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in LDL-C/HDL-C Ratio at Week 52 | -0.20805 | 0.18299 | -0.07681 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 26 | 0.08263 | -0.06860 | 0.04337 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in nonHDL-C/HDL-C Ratio at Week 52 | -0.23887 | 0.17170 | -0.10817 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 26 | 0.13029 | 0.17554 | 0.14191 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoA1 at Week 52 | 0.11047 | 0.07751 | 0.08580 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 26 | 0.06098 | -0.03181 | 0.03861 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB at Week 52 | -0.11217 | 0.11006 | -0.03932 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 26 | 0.02907 | -0.09476 | -0.00160 |
Correlation of changes from baseline in eGFR with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
| Correlation coefficient | Rosuvastatin | Atorvastatin | All Treatments |
|---|---|---|---|
| Correlation of Change From Baseline in eGFR With Percent Change From Baseline in ApoB/ApoA-1 Ratio at Week 52 | -0.15415 | 0.10486 | -0.06121 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rosuvastatin 10 mg | — | 10/69 (14.5%) | 15/69 (21.7%) |
| Rosuvastatin 40 mg | — | 6/87 (6.9%) | 16/87 (18.4%) |
| Atorvastatin 80 mg | — | 5/80 (6.3%) | 17/80 (21.3%) |
| Event | Rosuvastatin 10 mg | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|---|
| BronchitisInfections and infestations | 2/69 | 0/87 | 1/80 |
| Cardiac FailureCardiac disorders | 1/69 | 0/87 | 0/80 |
| Cardiac Failure CongestiveCardiac disorders | 1/69 | 0/87 | 0/80 |
| EnterocolitisGastrointestinal disorders | 1/69 | 0/87 | 0/80 |
| Lumbar Vertebral FractureInjury, poisoning and procedural complications | 1/69 | 0/87 | 0/80 |
| Fluid RetentionMetabolism and nutrition disorders | 1/69 | 0/87 | 0/80 |
| Intervertebral Disc ProtrusionMusculoskeletal and connective tissue disorders | 1/69 | 0/87 | 0/80 |
| Transitional Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/69 | 0/87 | 0/80 |
| Hypertensive EncephalopathyNervous system disorders | 1/69 | 0/87 | 0/80 |
| Renal ColicRenal and urinary disorders | 1/69 | 0/87 | 0/80 |
| Event | Rosuvastatin 10 mg | Rosuvastatin 40 mg | Atorvastatin 80 mg |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 3/69 | 6/87 | 7/80 |
| NauseaGastrointestinal disorders | 2/69 | 6/87 | 0/80 |
| MyalgiaMusculoskeletal and connective tissue disorders | 4/69 | 3/87 | 5/80 |
| BronchitisInfections and infestations | 4/69 | 0/87 | 0/80 |
| Blood Creatine Phosphokinase IncreasedInfections and infestations | 3/69 | 3/87 | 4/80 |
| DizzinessNervous system disorders | 0/69 | 1/87 | 4/80 |
| Age, Customized(Participants) | Rosuvastatin 10 mg | Rosuvastatin 40 mg | Atorvastatin 80 mg | Total |
|---|---|---|---|---|
| 18 to 49 years | 34 | 44 | 42 | 120 |
| 50 to 64 years | 31 | 31 | 30 | 92 |
| >=65 years | 5 | 12 | 8 | 25 |
| Sex: Female, Male(Participants) | Rosuvastatin 10 mg | Rosuvastatin 40 mg | Atorvastatin 80 mg | Total |
|---|---|---|---|---|
| Female | 28 (28 to —) | 35 (35 to —) | 31 (31 to —) | 94 (0 to 0) |
| Male | 42 (42 to —) | 52 (52 to —) | 49 (49 to —) | 143 (0 to 0) |
| Estimated glomerular filtration rate [eGFR](mL/min) | Rosuvastatin 10 mg | Rosuvastatin 40 mg | Atorvastatin 80 mg | Total |
|---|---|---|---|---|
| Mean | 78.315 ± 28.0653 | 76.774 ± 30.3878 | 71.464 ± 30.0156 | 75.419 ± 29.6012 |
| Urine albumin/creatinine ratio(mg/g) | Rosuvastatin 10 mg | Rosuvastatin 40 mg | Atorvastatin 80 mg | Total |
|---|---|---|---|---|
| Mean | 1023.165 ± 720.0251 | 1167.368 ± 865.4584 | 1069.103 ± 720.8011 | 1091.263 ± 775.1889 |
| Urine protein/creatinine ratio(mg/g) | Rosuvastatin 10 mg | Rosuvastatin 40 mg | Atorvastatin 80 mg | Total |
|---|---|---|---|---|
| Mean | 1301.163 ± 832.7398 | 1487.131 ± 1068.0642 | 1439.720 ± 991.2295 | 1416.023 ± 975.7636 |
Showing the first 100 of 107 sites across 11 countries. Choose a country and city above to see the rest.
The record gives a start of Feb 2006, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2010, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rosuvastatin · Atorvastatin